TABLE 4.
Binding of S. agalactiae strains to fibrinogen and presence of fbsA and fbsB genes in isolates correlated with clinical origin, serotype, and phylogenetic position of strains
| Strain group | No. (% ± SD) of strains in groupa:
|
|||||
|---|---|---|---|---|---|---|
| All strains (n = 111) |
fbsA+ fbsB+ (n = 55)
|
fbsA+ fbsB− (n = 35)
|
fbsA− fbsB− (n = 21) | |||
| 4-7 rs | Other no. of rs | 26 rs | Other no. of rs | |||
| Clinical origins | ||||||
| Vaginal | 36 (6.8 ± 5.7) | 12 (9.4 ± 6.7) | 4 (3.6 ± 1.6) | 1 (24.3) | 14 (4.4 ± 1.9) | 5 (6.0 ± 4.5) |
| Gastric | 21 (5.0 ± 4.2) | 3 (11.8 ± 6.9) | 1 (3.7) | 0 | 16 (4.0 ± 2.6) | 1 (2.8) |
| CSF | 54 (9.6 ± 7.6) | 30 (14.1 ± 7.0) | 5 (5.9 ± 2.7) | 0 | 4 (2.6 ± 1.6) | 15 (3.8 ± 2.9) |
| Polysaccharide serotypes | ||||||
| Ia | 16 (4.1 ± 1.6) | 6 (5.5 ± 1.4) | 7 (3.6 ± 1.2) | 0 | 3 (2.7 ± 0.7) | 0 |
| Ib | 12 (4.4 ± 2.2) | 0 | 0 | 0 | 12 (4.4 ± 2.2) | 0 |
| II | 17 (3.8 ± 3.2) | 0 | 0 | 0 | 9 (3.1 ± 2.0) | 8 (4.6 ± 4.0) |
| III | 55 (11.1 ± 7.3) | 36 (14.5 ± 6.7) | 3 (7.5 ± 2.1) | 0 | 4 (6.3 ± 3.1) | 12 (3.5 ± 2.3) |
| IV | 3 (6.4 ± 4.5) | 0 | 0 | 0 | 2 (4.3 ± 3.8) | 1 (10.5) |
| V | 3 (3.1 ± 1.0) | 0 | 0 | 0 | 3 (3.1 ± 1.0) | 0 |
| NT | 5 (9.2 ± 9.3) | 3 (5.8 ± 5.6) | 0 | 1 (24.3) | 1 (4.5) | 0 |
| Phylogenetic positions | ||||||
| MLEE Ib | 40 (13.3 ± 7.2) | 36 (14.2 ± 7.1) | 2 (7.5 ± 3.0) | 0 | 2 (4.1 ± 3.0) | 0 |
| ET 49 | 10 (14.0 ± 7.7) | 8 (15.6 ± 7.8) | 2 (7.5 ± 3.0) | 0 | 0 | 0 |
| ET 58 | 19 (15.1 ± 7.2) | 19 (15.1 ± 7.2) | 0 | 0 | 0 | 0 |
| Other ETs | 11 (9.8 ± 6.1) | 9 (11.0 ± 6.0) | 0 | 0 | 2 (4.1 ± 3.0) | 0 |
| MLEE IIc | 71 (4.7 ± 3.6) | 9 (6.7 ± 2.4) | 8 (4.1 ± 1.7) | 1 (24.3) | 32 (4.0 ± 2.3) | 21 (4.3 ± 3.3) |
| ET 11 | 6 (5.5 ± 1.7) | 2 (6.3 ± 0.2) | 4 (5.1 ± 2.0) | 0 | 0 | 0 |
| ET 12 | 15 (4.6 ± 2.6) | 3 (7.6 ± 0.9) | 0 | 0 | 1 (5.9) | 11 (3.6 ± 2.4) |
| Other ETs | 50 (4.6 ± 4.0) | 4 (6.3 ± 3.7) | 4 (3.1 ± 0.5) | 1 (24.3) | 31 (3.9 ± 2.3) | 10 (5.0 ± 4.1) |
| Sequence type | ||||||
| ST-17 | 41 (13.6 ± 6.9) | 40 (13.6 ± 7.0) | 1 (9.7) | 0 | 0 | 0 |
| Non-ST-17 | 70 (4.5 ± 3.4) | 5 (5.2 ± 1.4) | 9 (4.2 ± 1.7) | 1 (24.3) | 34 (4.0 ± 2.2) | 21 (4.3 ± 3.3) |
a
%, mean percentage of binding to fibrinogen; +, present; −, absent.
b
In MLEE division I, no significant difference was observed between the mean percentages of binding to fibrinogen of strains from ET 49 and ET 58 (mostly composed of isolates from CSF) and strains from other ETs.
c
In MLEE division II, no significant difference was observed between the mean percentages of binding to fibrinogen of strains from ET 11 and ET 12 (mostly composed of isolates from CSF) and strains from other ETs.